Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology

Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology




Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology

First full-solution sale endorsing Ikonisys business model and paving the way for further sales activity

PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the first sale of an Ikoniscope20 digital fluorescence microscope solution together with its optimized reagents.

As announced during the IPO of Ikonisys, the primary initial focus of the commercialization strategy for the United States is to convert current customers into Ikoniscope20 users. An active user of Ikonisys’ former Ikoniscope Gen1 platform up to today, Comprehensive Urology has decided to upgrade its system to the Ikoniscope20 and at the same time to utilize the optimized reagents provided by Ikonisys to perform its bladder cancer molecular diagnosis.

Ikonisys’ business model is to sell a fully integrated solution comprising hardware, software and consumables. Reagents, needed to perform each single test, are an essential part of the molecular diagnostics market. Ikonisys is offering clients optimized reagents at a competitive rate, ensuring greater performance with the ikoniscope20.

The Ikoniscope20 combined with Ikonisys’ FISH probes will automate early bladder cancer diagnosis, allowing Comprehensive Urology to perform several thousand tests per year.

Please find the full press release on the investors website.

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.Ikonisys.com

Contacts

Ikonisys
Alessandro Mauri

CFO

investors@ikonisys.com

NewCap
Olivier Bricaud / Louis-Victor Delouvrier

Investor Relations

Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 92

NewCap
Nicolas Merigeau

Media Relations

Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98